Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia

Psychoneuroendocrinology

Volumn 36, Issue 7, 2011, Pages 1092-1096

  Guest, Paul C ^a   Schwarz, Emanuel ^a   Krishnamurthy, Divya ^a   Harris, Laura W ^a   Leweke, F Markus ^b   Rothermundt, Matthias ^c   van Beveren, Nico J M ^d   Spain, Michael ^e   Barnes, Anthony ^e   Steiner, Johann ^f   Rahmoune, Hassan ^a   Bahn, Sabine ^a,g  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e Rules Based Medicine Inc   (United States)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adrenal gland; Growth hormone; Insulin; Multiplex immunoassay; Pituitary; Schizophrenia

Indexed keywords

ADIPONECTIN; CHROMOGRANIN A; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A [DEARGININE]; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE; FOLLITROPIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE; HYDROCORTISONE; INSULIN; LEPTIN; LUTEINIZING HORMONE; PANCREAS POLYPEPTIDE; PEPTIDE YY; PROGESTERONE; PROLACTIN; RESISTIN; SECRETIN; SOMATOMEDIN C; TESTOSTERONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOASSAY; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; AGE OF ONSET; AUTOPSY; CASE-CONTROL STUDIES; COHORT STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN; MALE; NEUROENDOCRINE CELLS; PITUITARY GLAND; PITUITARY-ADRENAL SYSTEM; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79954576068     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.12.018     Document Type: Article

References (22)

1. Akamine E.H., Marçal A.C., Camporez J.P., Hoshida M.S., Caperuto L.C., Bevilacqua E., Carvalho C.R. Obesity induced by high-fat diet promotes insulin resistance in the ovary. J. Endocrinol. 2010, 206:65-74.
2. Asakawa A., Inui A., Yuzuriha H., Ueno N., Katsuura G., Fujimiya M., Fujino M.A., Niijima A., Meguid M.M., Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003, 124:1325-1336.
3. Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone. Trends Endocrinol. Metab. 2006, 17:110-116.
4. Cheng T.M., Lu Y.E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Ma D., Stelzhammer V., Umrania Y., Wayland M.T., Lió P., Bahn S. Identification of targeted analyte clusters for studies of schizophrenia. Mol. Cell. Proteomics 2010, 9:510-522.
5. Domenici E., Willé D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., Brittain C., Rujescu D., Giegling I., Turck C.W., Holsboer F., Bullmore E.T., Middleton L., Merlo-Pich E., Alexander R.C., Muglia P. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010, 5(2):e9166.
6. Friese R.S., Gayen J.R., Mahapatra N.R., Schmid-Schönbein G.W., O'Connor D.T., Mahata S.K. Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. Physiol. Genomics 2010, 40:195-207.
7. Goldstein J.M. Sex, hormones and affective arousal circuitry dysfunction in schizophrenia. Horm. Behav. 2006, 50:612-622.
8. Guest P.C., Wang L., Harris L.W., Burling K., Levin Y., Ernst A., Wayland M.T., Umrania Y., Herberth M., Koethe D., van Beveren J.M., Rothermundt M., McAllister G., Leweke F.M., Steiner J., Bahn S. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic nai{dotless}ve schizophrenia patients. Mol. Psychiatry 2010, 15:117-119.
9. Helle K.B., Corti A., Metz-Boutigue M.H., Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell. Mol. Life Sci. 2007, 64:2863-2886.
10. Kahn R.S., Davidson M., Hirschowitz J., Stern R.G., Davis B.M., Gabriel S., Moore C., Davis K.L. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects. Psychiatry Res. 1992, 41:155-161.
11. Kalkhoff R.K. Metabolic effects of progesterone. Am. J. Obstet. Gynecol. 1982, 142:735-738.
12. Meltzer H.Y., Lee M.A., Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology 2001, 24:278-290.
13. Meyer J.M., Davis V.G., McEvoy J.P., Goff D.C., Nasrallah H.A., Davis S.M., Daumit G.L., Hsiao J., Swartz M.S., Stroup T.S., Lieberman J.A. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr. Res. 2008, 101:273-286.
14. Murray R.D., Shalet S.M. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency. Clin. Endocrinol. 2005, 62:182-188.
15. Nilsson B.M., Hultman C.M., Wiesel F.A. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. Prostaglandins Leukot. Essent. Fatty Acids 2006, 74:339-346.
16. Nosadini R., Del Prato S., Tiengo A., Valerio A., Muggeo M., Opocher G., Mantero F., Duner E., Marescotti C., Mollo F., Belloni F. Insulin resistance in Cushing's syndrome. J. Clin. Endocrinol. Metab. 1983, 57:529-536.
17. Ryan M.C., Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002, 71:239-257.
18. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J.P., Guest P.C., Rahmoune H., Pietsch S., Leweke F.M., Rothermundt M., Steiner J., Koethe D., Kranaster L., Ohrmann P., Suslow T., Levin Y., Bogerts B., van Beveren N.J., McAllister G., Weber N., Niebuhr D., Cowan D., Yolken R.H., Bahn S. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 2010, 5:39-47.
19. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
20. Swatton J.E., Prabakaran S., Karp N.A., Lilley K.S., Bahn S. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol. Psychiatry 2004, 9:128-143.
21. Tannenbaum G.S., Martin J.B., Colle E. Ultradian growth hormone rhythm in the rat: effects of feeding, hyperglycemia, and insulin-induced hypoglycemia. Endocrinology 1976, 99:720-727.
22. Walker J.J., Terry J.R., Lightman S.L. Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. Proc. Biol. Sci. 2010, 277:1627-1633.